Profile data is unavailable for this security.
About the company
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
- Revenue in HKD (TTM)62.05m
- Net income in HKD-585.97m
- Incorporated2018
- Employees178.00
- LocationAntengene Corp LtdUgland HousePO Box 309SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.antengene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
China Health Group Inc | 27.33m | -62.73m | 195.09m | 41.00 | -- | 1.91 | -- | 7.14 | -0.063 | -0.063 | 0.0275 | 0.1025 | 0.1547 | -- | 0.2559 | 650,603.80 | -35.50 | 6.84 | -47.26 | 9.52 | 42.55 | 74.98 | -229.55 | 19.19 | -- | -1,310.95 | 0.00 | 0.00 | 63.67 | -18.51 | -267.82 | -- | 30.37 | -- |
Sirnaomics Ltd | 0.00 | -635.21m | 365.45m | 90.00 | -- | 192.87 | -- | -- | -8.37 | -8.37 | 0.00 | 0.0216 | 0.00 | -- | -- | 0.00 | -110.32 | -- | -136.58 | -- | -- | -- | -- | -- | -- | -3.26 | -- | -- | -- | -- | 10.88 | -- | -- | -- |
Clover Biopharmaceuticals Ltd | 31.98m | -978.55m | 518.82m | 323.00 | -- | -- | -- | 16.22 | -0.7846 | -0.7846 | 0.0256 | -0.7105 | 0.0119 | 0.014 | 98.80 | 82,632.11 | -36.27 | -- | -405.86 | -- | 54.86 | -- | -3,060.03 | -- | 0.4426 | -- | -- | -- | -- | -- | 94.35 | -- | -- | -- |
Kintor Pharmaceutical Ltd | 0.00 | -1.02bn | 599.65m | 175.00 | -- | 1.38 | -- | -- | -2.37 | -2.37 | 0.00 | 0.9683 | 0.00 | 0.1411 | -- | 0.00 | -70.41 | -50.15 | -87.57 | -58.43 | -- | -27.62 | -- | -10,511.41 | 1.56 | -282.63 | 0.3788 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
HighTide Therapeutics Inc | 0.00 | -664.52m | 725.83m | 68.00 | -- | 1.10 | -- | -- | -1.43 | -1.43 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.01 | -- | -118.34 | -- | -- | -- | -- | -- | -- | -- | 0.0404 | -- | -- | -- | -393.76 | -- | -- | -- |
Antengene Corp Ltd | 62.05m | -585.97m | 776.12m | 178.00 | -- | 0.7059 | -- | 12.51 | -0.95 | -0.95 | 0.1005 | 1.63 | 0.035 | 0.6597 | 1.57 | 308,681.80 | -33.06 | -53.57 | -37.16 | -58.94 | 84.84 | -- | -944.43 | -1,987.01 | 5.66 | -- | 0.1663 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
JW (Cayman) Therapeutics Co Ltd | 191.37m | -694.78m | 843.28m | 323.00 | -- | 0.5138 | -- | 4.41 | -1.68 | -1.68 | 0.4639 | 3.95 | 0.0747 | 1.87 | 11.48 | 480,819.20 | -27.11 | -39.77 | -31.71 | -44.00 | 50.40 | -- | -363.06 | -1,316.81 | 2.76 | -- | 0.2043 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
Sunho Biologics Inc | 0.00 | -118.73m | 853.83m | 124.00 | -- | 1.41 | -- | -- | -0.574 | -0.574 | 0.00 | 3.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.77 | -300.76 | 0.0516 | -- | -- | -- | -155.25 | -- | -- | -- |
Brii Biosciences Ltd | 0.00 | -293.74m | 943.20m | 95.00 | -- | 0.2976 | -- | -- | -0.4025 | -0.4025 | 0.00 | 4.34 | 0.00 | -- | -- | 0.00 | -8.89 | -- | -9.01 | -- | -- | -- | -- | -- | -- | -- | 0.007 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
Genor Biopharma Holdings Ltd | 16.01m | -581.53m | 1.02bn | 28.00 | -- | 0.8617 | -- | 63.97 | -1.15 | -1.15 | 0.0315 | 2.29 | 0.0093 | 0.0178 | 0.2277 | 153,966.80 | -33.87 | -55.46 | -39.06 | -63.73 | 97.59 | 66.56 | -3,638.27 | -14,819.18 | 5.73 | -- | 0.003 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
Data as of Oct 09 2024. Currency figures normalised to Antengene Corp Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research (Hong Kong) Ltd.as of 30 Jun 2024 | 8.90m | 1.32% |
Zeal Asset Management Ltd.as of 31 Dec 2023 | 6.32m | 0.94% |
Norges Bank Investment Managementas of 31 Dec 2023 | 1.82m | 0.27% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.51m | 0.22% |
Dimensional Fund Advisors LPas of 03 Jul 2024 | 677.50k | 0.10% |
Dimensional Fund Advisors Ltd.as of 31 May 2024 | 60.23k | 0.01% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 17.50k | 0.00% |
American Century Investment Management, Inc.as of 30 Jun 2024 | 12.50k | 0.00% |
DFA Australia Ltd.as of 30 Jun 2024 | 2.50k | 0.00% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.